RxDoctor Payments Data

Mark Viegas, MD

Family Medicine · Little Rock, ARNPI 1841589017

Payments from drug & device makers

$5,264in general payments, 2019–2025

Across 317 payments — averaging $16.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$907
  • Johnson & Johnson$858
  • Abbott$374
  • Novartis$325
  • Pfizer$248
  • GSK$246
  • plus $2K from 27 others

What the payments were for

  • Food & beverage$5,264100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,264 in reported general payments places this provider in the 85th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$60,740
Medicare patients
420
Services billed
1,645

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TradjentaLinagliptin28$29,065
EliquisApixaban16$24,335
XareltoRivaroxaban14$17,954
JardianceEmpagliflozin11$17,528
Breo ElliptaFluticasone/Vilanterol17$9,855
MyrbetriqMirabegron13$7,353
Atorvastatin Calcium482$3,859
Albuterol Sulfate HfaAlbuterol Sulfate145$3,386
Omega-3 Acid Ethyl Esters26$2,318
Amlodipine Besylate328$1,645
Levothyroxine Sodium152$1,623
Famotidine96$1,541
Metoprolol Succinate118$1,149
Omeprazole71$1,135
Carvedilol157$1,116

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimTradjenta, Jardiance$138$46,59339 claims
PfizerEliquis$248$24,33516 claims
Johnson & JohnsonXarelto$858$17,95414 claims
GSKBreo Ellipta$246$9,85517 claims
Astellas Pharma US IncMyrbetriq$16$7,35313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →